Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib
We present the case of a 26-year-old patient with a recurrent MB, in which next-generation sequencing (FoundationOne CDx) revealed a mutation in PTCH1, allowing the patient to be treated with vismodegib in second line, resulting in a durable benefit lasting for 1 year. Using an in-house digital PCR probe, the PTCH1 mutation could be tracked in ctDNA during treatment with first-line chemotherapy and while on treatment with vismodegib, demonstrating a precise correlation with the radiological and clinical behavior of the disease.PMID:38438322 | DOI:10.1093/oncolo/oyae026 (Source: The Oncologist)
Source: The Oncologist - March 4, 2024 Category: Cancer & Oncology Authors: Santiago Cabezas-Camarero Vanesa Garc ía-Barberán Rebeca P érez-Alfayate Mar ía Elena Gómez Del Pulgar Maria Nieves Cabrera-Martin Isabel Casado-Fari ñas Pedro P érez-Segura Source Type: research

Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
CONCLUSION: Due to the rarity of MBC, this study highlights important findings from real clinical practice. Although the number of patients with MBC with unfavorable features was higher in this Czech dataset than in international studies, the prognosis remains consistent with real-world evidence.PMID:38431780 | DOI:10.1093/oncolo/oyae031 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Zuzana Bielcikova Milos Holanek Iveta Selingerova Ondrej Sorejs Iveta Kolarova Renata Soumarova Jan Proks Lucie Reifova Vlastimila Cmejlova Lenka Linkova Michaela Zabojnikova Martina Chodacka Lucie Janovska Lenka Lisnerova Karolina Kasparova Denisa Pohank Source Type: research

Two Hematological Markers Predicting the Efficacy and Prognosis of Neoadjuvant Chemotherapy Using Lobaplatin Against Triple-Negative Breast Cancer
CONCLUSION: PLR and NLR could be used to predict the efficacy of neoadjuvant therapy with the taxane, anthracycline, and lobaplatin regimen for patients with TNBC, as patients who had lower PLR and NLR values had a higher tpCR rate and a better long-term prognosis.PMID:38431781 | DOI:10.1093/oncolo/oyae025 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Cheng Wang Qiyun Shi Guozhi Zhang Xiujuan Wu Wenting Yan Andi Wan Siyi Xiong Long Yuan Hao Tian Dandan Ma Jun Jiang Xiaowei Qi Yi Zhang Source Type: research

Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis
CONCLUSION: Patient's SB seems to carry a prognostic significance. ESAS and physician-reported ECOG exhibit comparable prognostic values. Physicians and patients can frequently have divergent opinions on PS. ESAS takes a patient-centered approach and should be encouraged in practice among patients with GEC as an additional tool for prognostication.PMID:38431782 | DOI:10.1093/oncolo/oyae010 (Source: The Oncologist)
Source: The Oncologist - March 3, 2024 Category: Cancer & Oncology Authors: Thais Baccili Cury Megid Divya Sharma Zeynep Baskurt Lucy Xiaolu Ma Xin Wang Carly C Barron Raymond Woo-Jun Jang Eric Xueyu Chen Carol Jane Swallow Aruz Mesci Jonathan Yeung Rebecca K S Wong Savtaj Singh Brar Patrick Veit-Haibach John Kim Yvonne Bach Hiro Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes
CONCLUSION: Our findings demonstrated improved outcomes with upfront 1L TT versus non-TT in patients with aNSCLC with ADOs and observed timely switching to TT after biomarker test result had similar outcomes to Upfront TT. Opportunities remain to improve the use of NGS for early ADO identification and determination of 1L TT.PMID:38417095 | DOI:10.1093/oncolo/oyae022 (Source: The Oncologist)
Source: The Oncologist - February 28, 2024 Category: Cancer & Oncology Authors: Thomas Stricker Neha Jain Esprit Ma Elaine Yu Rongrong Wang Robert Schuldt Richard Price Tania Szado Jesse Sussell Sarika Ogale Victor Lin Edward Arrowsmith Dennis Slater Daniel Vaena Harry Staszewski Bruno Fang Lasika Seneviratne Davey Daniel Source Type: research

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC
CONCLUSION: A well-designed DNA CGP assay is capable of robust fusion detection and these fusion calls are reliable for informing clinical decision-making. While DNA CGP detects most driver fusions, the clinical impact of fusion detection is substantial for individual patients and exhaustive efforts, inclusive of additional RNA-based testing, should be considered when an oncogenic driver is not clearly identified.PMID:38401173 | DOI:10.1093/oncolo/oyae028 (Source: The Oncologist)
Source: The Oncologist - February 24, 2024 Category: Cancer & Oncology Authors: Philip C Mack Rachel B Keller-Evans Gerald Li Katherine T Lofgren Alexa B Schrock Sally E Trabucco Justin M Allen Khaled Tolba Geoffrey R Oxnard Richard S P Huang Source Type: research

Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019 (Source: The Oncologist)
Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research